Revolutionizing Kidney Cancer Treatment: A Minimally Invasive Approach
A groundbreaking study conducted in Denmark has revealed a promising alternative to traditional surgery for treating small kidney cancers. The research, published in Radiology, a journal of the Radiological Society of North America, introduces a minimally invasive procedure called ablation, which has proven to be as effective as surgery with faster recovery and fewer complications.
The study, led by Iben Lyskjær, Ph.D., M.Sc., an associate professor at Aarhus University and Aarhus Hospital, focused on patients with stage T1a renal cell carcinoma, a cancer often discovered incidentally during CT scans for other conditions. This cancer is becoming increasingly prevalent, putting a strain on healthcare systems.
Ablation, an image-guided procedure using extreme heat (radiofrequency ablation) or cold (cryoablation) to destroy tumors, has gained popularity since its introduction in Denmark in 2006. The study compared outcomes between patients treated with ablation and those treated with surgery, involving 1,862 patients over a decade.
Interestingly, the study found no significant difference in cancer progression risk between the ablation and resection groups. However, local recurrence was more common after ablation (2.41%) compared to resection and nephrectomy (1.20% and 0%, respectively). Despite this, Dr. Lyskjær assures that recurrent tumors can be treated successfully with another ablation or surgery, and local recurrences did not impact overall survival.
The study also highlighted the benefits of ablation in reducing hospital stays and post-treatment contacts. Patients who underwent ablation had the shortest hospital stays and the fewest 30-day post-treatment hospital visits, indicating fewer complications. Additionally, distant metastasis, a concern with nephrectomy, was less frequent in ablation patients.
Dr. Lyskjær emphasizes the importance of considering minimally invasive approaches as broader treatment options, especially for incidentally discovered tumors, whose aggressive potential is uncertain. She suggests that treatment choices should be patient-centered, considering individual characteristics and preferences, with informed decisions made through shared decision-making processes.
